BCR/ABL Transcript At 3 Months Predicts Long-Term Outcomes Following Second Generation Tyrosine Kinase Inhibitor Therapy in the Patients with CML in Chronic Phase Who Failed Imatinib.

@inproceedings{Kim2012BCRABLTA,
  title={BCR/ABL Transcript At 3 Months Predicts Long-Term Outcomes Following Second Generation Tyrosine Kinase Inhibitor Therapy in the Patients with CML in Chronic Phase Who Failed Imatinib.},
  author={Dennis Dong Hwan Kim and Hong Gi Lee and Suzanne Kamel-Reid and Jeffrey Lipton},
  year={2012}
}
Abstract 2777 Background: The BCR/ABL transcript level at 3 months can predict long-term outcomes following frontline therapy with Imatinib or Dasatinib in chronic myeloid leukemia (CML) patients. However, data is lacking with second generation tyrosine kinase inhibitor (2GTKI) therapy after Imatinib failure. Methods: A total of 112 patients with CML in chronic phase (CP) receiving 2GTKI after Imatinib failure were reviewed. Treatment outcomes including complete cytogenetic (CCyR), major… CONTINUE READING

Citations

Publications citing this paper.

Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors

VIEW 2 EXCERPTS
CITES BACKGROUND